0001477932-23-005410.txt : 20230719 0001477932-23-005410.hdr.sgml : 20230719 20230719143555 ACCESSION NUMBER: 0001477932-23-005410 CONFORMED SUBMISSION TYPE: 8-A12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230719 DATE AS OF CHANGE: 20230719 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNexus Gene Lab Corp CENTRAL INDEX KEY: 0001737523 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 262124961 STATE OF INCORPORATION: WY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-A12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-41750 FILM NUMBER: 231096421 BUSINESS ADDRESS: STREET 1: 10-2 TOWER B, VERTICAL BUSINESS SUITE, STREET 2: 8 JALAN KERINCHI, CITY: KUALA LUMPUR STATE: N8 ZIP: 59200 BUSINESS PHONE: 60122126512 MAIL ADDRESS: STREET 1: 10-2 TOWER B, VERTICAL BUSINESS SUITE, STREET 2: 8 JALAN KERINCHI, CITY: KUALA LUMPUR STATE: N8 ZIP: 59200 FORMER COMPANY: FORMER CONFORMED NAME: BioNexus Gene Lab Coporation DATE OF NAME CHANGE: 20180413 8-A12B 1 bglc_8a12b.htm FORM 8-A12B bglc_8a12b.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-A

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR 12(g) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

BioNexus Gene Lab Corp.

(Exact name of registrant as specified in its charter)

 

Wyoming

 

35-2604830

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

Unit 02, Level 10 Tower B, Avenue 3, The Vertical

Business Suite II Bangsar South No. 8 Jalan Kerinchi

Kuala Lumpur, Malaysia

(Address of principal executive offices)

 

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class to be so registered

 

Name of each exchange on which each class is to be registered

Shares of Common Stock, no par value

 

The Nasdaq Stock Market LLC

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. ☒

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. ☐

 

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

 

Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333-269753

 

Securities to be registered pursuant to Section 12(g) of the Act: None

 

 

 

 

Item 1. Description of Registrant’s Securities to be Registered.

 

The description of shares of common stock, no par value, of  BioNexus Gene Lab Corp. (the “Registrant”) to be registered hereunder is set forth under the heading “Description of Capital Stock” in the Registrant’s Registration Statement on Form S-1 (File No. 333-269753) originally filed with the Securities and Exchange Commission on February 14, 2023, as amended by any amendments to such Registration Statement and by any prospectus subsequently filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which information is incorporated herein by reference.

 

Item 2. Exhibits.

 

Pursuant to the “Instructions as to Exhibits” with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

 

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

  

 

BioNexus Gene Lab Corp.

 

 

 

 

 

Date: July 19, 2023

By:

/s/ Sook Keng Yeoh

 

 

Name: 

Sook Keng Yeoh

 

 

Title:

Chief Executive Officer and Director

 

 

 

3